Bionomics Income from Continuous Operations 2022-2024 | NEUP
Bionomics income from continuous operations from 2022 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Bionomics Annual Income from Continuous Operations
(Millions of US $) |
| 2024 |
$-15 |
| 2023 |
$-21 |
| 2022 |
$-16 |
| 2021 |
$-6 |
Bionomics Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$-1 |
| 2024-06-30 |
|
| 2023-12-31 |
|
| 2023-09-30 |
$-5 |
| 2023-06-30 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.007B |
$0.000B |
|
Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| Kidpik (PIKM) |
United States |
$0.000B |
0.00 |
